L. Hart

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer

Alberto Chiappori, Tatjana Kolevska, David R. Spigel et al. · Annals of Oncology · 2014 · 177 citations · Full text

Telomerase Inhibitor Imetelstat, Medicine, Pharmacology +7

Efficacy of Bedtime NPH Insulin With Daytime Sulfonylurea for Subpopulation of Type II Diabetic Subjects

Matthew C. Riddle, L. Hart, Donald J. Bouma et al. · Diabetes Care · 1989 · 74 citations

Obesity, Metabolic Syndrome, Type Ii Diabetes +15

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

G. N. Hortobágyi, Salomon M. Stemmer, H.A. Burris et al. · Annals of Oncology · 2021 · 73 citations

Endocrine Oncology, Breast Oncology, Phase Iii Monaleesa-2 +9

Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT

Howard S. Höchster, Axel Grothey, L. Hart et al. · Annals of Oncology · 2014 · 65 citations · Full text

Intermittent Oxaliplatin Strategy, Oncology, Pharmacology +5

A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

Louis Fehrenbacher, V J O'Neill, Chandra P. Belani et al. · Journal of Clinical Oncology · 2006 · 63 citations

Cancer Pharmacology, Pharmacotherapy, Oncology +17